A Once-a-Week Insulin Controlled Blood Sugar as Well as a Daily One

CATEGORY: METABOLIC & BLOOD SUGAR

For most people with type 2 diabetes, starting insulin has meant a needle every day, indefinitely. That’s part of why so many put the decision off. A yearlong trial of 795 adults starting insulin for the first time found the weekly option held its own: once-weekly efsitora lowered HbA1c, the standard three-month blood-sugar average, by 1.19 points, against 1.16 with the daily standby insulin glargine.¹ Serious or symptomatic low-blood-sugar episodes were 43% less frequent with the weekly shot. The FDA approved efsitora for adults with type 2 diabetes in September, under the name Onswik.

One needle a week, and far fewer decisions

Everyone in the trial had type 2 diabetes that pills and other treatments were no longer controlling, and none had used insulin before. Each participant was dealt one of two routines at random, and followed it for 52 weeks. One group injected insulin glargine daily, adjusting the dose as often as weekly to chase a fasting glucose target, the way basal insulin is usually managed. The other injected efsitora once a week at one of four fixed doses, stepped up only every four weeks, more like moving between tablet strengths than titrating a drip. The simpler routine showed in the numbers. Efsitora users made a median of 2 dose changes over the year. Glargine users made 8. Eli Lilly, efsitora’s maker, funded the trial.

Equal control, fewer lows

The feared trade-off didn’t show up. Blood-sugar control ended up statistically equivalent, and the rate of significant or severe hypoglycemia (blood sugar low enough to cause symptoms or require help) was 0.50 events per person per year with efsitora versus 0.88 with glargine. A week’s worth of insulin in one injection sounds risky, but the drug is built to release so gradually that its level barely ripples day to day. The approval covers type 2 diabetes only. People with type 1 diabetes, and anyone already on multiple daily insulins, were outside this trial’s question.

Key Takeaways

• Once-weekly insulin efsitora matched daily glargine on blood-sugar control over 52 weeks in adults with type 2 diabetes new to insulin, with a median of 2 dose adjustments in a year versus 8.
• Significant or severe low-blood-sugar episodes were 43% less frequent with the weekly insulin (0.50 vs 0.88 events per person per year).
• Efsitora is now FDA-approved for type 2 diabetes; the trial says nothing about type 1 diabetes or mealtime insulin.

References

1. Rosenstock J, Bailey T, Connery L, et al. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. New England Journal of Medicine. 2025;393(4):325–335. link